Cabaletta Bio (CABA) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

CABA Cabaletta Bio

Watchlist

3.010
+0.590+24.38%

Close Nov 27 16:00 ET

3.150
+0.140+4.65%

Post 20:01 ET

147.12MMarket Cap-1393P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Cabaletta Bio Presents Positive Data On CABA-201 At ACR Convergence 2024
RTTNewsNov 26 09:30 ET
Cabaletta Bio to Participate in Upcoming Investor Conferences in December
GlobeNewswireNov 26 08:00 ET
Cabaletta Bio Reports Q3 2024 Financial Results
TipRanksNov 18 22:54 ET
Express News | Cabaletta Bio Announces Presentation Of Updated CABA-201 Clinical Data At ACR Convergence 2024l; Says Safety Profile Suggested Favorable Risk-Benefit With No CRS Or ICANS In Majority Of Patients
BenzingaNov 18 07:22 ET
Cabaletta Bio's CABA-201 Shows Results in Autoimmune Disease Trials
BenzingaNov 18 07:11 ET
William Blair Maintains Cabaletta Bio(CABA.US) With Buy Rating
Moomoo NewsNov 18 04:33 ET · Ratings

Comments

Dps

Nov 19 14:57

$Cabaletta Bio (CABA.US)$ what happened to it

Dps

Oct 10 14:04

$Cabaletta Bio (CABA.US)$ poor stock … not growing at all

Dps

Oct 4 14:30

$Cabaletta Bio (CABA.US)$ what happened to it … no improvement at all

Jaguar8

Sep 25 15:39

NEWS

$Cabaletta Bio (CABA.US)$
Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024
Cabaletta Bio (Nasdaq: CABA) announced two presentations at the upcoming American College of Rheumatology (ACR) Convergence 2024, featuring new and updated clinical data on CABA-201, their 4-1BB-containing fully human CD19-CAR T cell investigational therapy. The presentations will cover:
1. An oral presentation on the safety and efficacy of C...